Compare · GKOS vs MDLN
GKOS vs MDLN
Side-by-side comparison of Glaukos Corporation (GKOS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.00B, about 6.7x GKOS ($7.19B).
- Over the past year, GKOS is up 25.3% and MDLN is down 8.9% - GKOS leads by 34.1 points.
- MDLN has been more active in the news (21 items in the past 4 weeks vs 11 for GKOS).
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- Medline Inc.
- Price
- $124.22+1.26%
- $37.13+1.64%
- Market cap
- $7.19B
- $48.00B
- 1M return
- -8.91%
- -3.70%
- 1Y return
- +25.26%
- -8.88%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- 2025
- News (4w)
- 11
- 21
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Latest GKOS
- Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wen Leana was granted 1,878 shares, increasing direct ownership by 10% to 21,617 units (SEC Form 4)
- Director Weisner Aimee S was granted 1,878 shares, increasing direct ownership by 10% to 20,684 units (SEC Form 4)
- Director Torres Denice was granted 1,878 shares, increasing direct ownership by 8% to 24,212 units (SEC Form 4)
- Director Foley Mark J was granted 1,878 shares, increasing direct ownership by 3% to 60,267 units (SEC Form 4)
- Director Hoffmeister David F was granted 1,878 shares, increasing direct ownership by 4% to 49,549 units (SEC Form 4)
- Director Kliman Gilbert H was granted 1,878 shares, increasing direct ownership by 5% to 37,406 units (SEC Form 4)
- Director Stapley Marc was granted 1,878 shares, increasing direct ownership by 5% to 39,327 units (SEC Form 4)
- SEC Form SD filed by Glaukos Corporation
- Director Hoffmeister David F exercised 15,000 shares at a strike of $24.69, increasing direct ownership by 46% to 47,671 units (SEC Form 4)
Latest MDLN
- Principal Accounting Officer Corcoran Jessi L bought $170,750 worth of shares (5,000 units at $34.15) (SEC Form 4)
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update